Shares of microcap biotech developer Adeona Pharmaceuticals (AEN) soar over 23% after reporting...

|By:, SA News Editor

Shares of microcap biotech developer Adeona Pharmaceuticals (AEN) soar over 23% after reporting successful results from its pilot Phase I/II safety study of oral high dose zinc therapy in ALS, also known as Lou Gehrig's disease.